FCA Corp TX Has $740,000 Stake in Astrazeneca Plc $AZN

FCA Corp TX lowered its stake in Astrazeneca Plc (NYSE:AZN) by 50.0% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,750 shares of the company’s stock after selling 3,750 shares during the quarter. FCA Corp TX’s holdings in Astrazeneca were worth $740,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Swiss National Bank bought a new position in Astrazeneca during the first quarter worth $1,202,714,000. SEB Asset Management AB bought a new stake in Astrazeneca in the first quarter valued at $1,157,593,000. Bank of New York Mellon Corp increased its stake in Astrazeneca by 546.1% in the first quarter. Bank of New York Mellon Corp now owns 6,667,812 shares of the company’s stock valued at $1,315,026,000 after purchasing an additional 5,635,812 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Astrazeneca by 552.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,547,597 shares of the company’s stock valued at $973,603,000 after purchasing an additional 4,697,895 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its holdings in shares of Astrazeneca by 4,529.1% during the first quarter. DekaBank Deutsche Girozentrale now owns 3,783,927 shares of the company’s stock valued at $747,099,000 after purchasing an additional 3,702,185 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AZN. HSBC downgraded Astrazeneca from a “buy” rating to a “hold” rating in a research note on Monday, July 13th. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $211.00.

Astrazeneca Trading Down 0.8%

NYSE AZN opened at $168.41 on Friday. The firm has a market capitalization of $261.19 billion, a P/E ratio of 25.29, a PEG ratio of 1.38 and a beta of 0.24. The business has a fifty day simple moving average of $180.80 and a 200 day simple moving average of $188.05. Astrazeneca Plc has a 12 month low of $142.98 and a 12 month high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The firm had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. On average, analysts predict that Astrazeneca Plc will post 10.22 EPS for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.